Thyroid Nodule Surveillance Protocol
ATA 2015 and ACR TI-RADS 2017 guidelines define thyroid nodule surveillance by risk category: TR5/high suspicion annually, TR4/intermediate 1–2 yearly, TR3/low suspicion every 2–3 years, and TR1–2/very low suspicion may not need follow-up beyond 5 years.
For Thyroid Nodule Surveillance Protocol, the thyroid and parathyroid surgery context connects the reported complaint with objective findings and a safe review frame. ATA 2015 and ACR TI-RADS 2017 guidelines define thyroid nodule surveillance by risk category: TR5/high suspicion annually, TR4/intermediate 1–2 yearly, TR3/low suspicion every 2–3 years, and TR1–2/very low suspicion may not need follow-up beyond 5 years. Previous care response, daily functional effect and associated risks make this topic more precise. this term assessment interprets neck examination, the finding nodule behavior, this entry hormone balance, the clinical point vocal fold mobility and the dictionary entry family history together. The entry strengthens preparation for consultation rather than deciding care. A clinical view of this topic interprets anatomical or symptom definitions together with daily-life impact: Growth criterion: ≥20% increase in two dimensions or ≥2 mm growth (in ≥2 measurements) is significant and triggers biopsy. This keeps repeat testing burden and delayed diagnosis risk in the same frame.
The first step in this term assessment is placing the complaint on a timeline. Onset, progression, side, comorbidities and response to previous care are documented separately. the dictionary entry review may combine ultrasound findings, this topic laboratory results, this term fine-needle biopsy and the finding laryngoscopic vocal fold assessment when useful. this entry decisions weigh nodule size, the clinical point ultrasound pattern, the dictionary entry lymph-node appearance, this topic prior biopsy result and this term risk profile separately. The examination plan for the finding is built around duration, side, progression and associated risks rather than one symptom alone: When subclinical thyrotoxicosis or suppressed TSH is present, functional scintigraphic evaluation takes priority. Previous reports can therefore improve decision quality. Additional tests matter only when they answer the clinical question that remains after examination.
Management of this topic aims for more than quick symptom relief; it protects durable function and safety. Medication, rehabilitation, procedures and this term surgery are compared within the same risk-benefit frame. the finding planning discusses observation, this entry medical adjustment, the clinical point lobectomy-total thyroidectomy, the dictionary entry parathyroid strategy or this topic neck dissection by findings. Management of this term aims to improve quality of life while protecting breathing, the finding safety, hearing, swallowing and oncologic risk separately. Decisions may be delayed when expectations and objective findings do not align.
this entry review tracks more than symptom score; daily function, safety boundaries and treatment response are read together. this term follow-up reviews calcium balance, the finding voice quality, this entry wound healing, the clinical point pathology results and the dictionary entry hormone replacement together. For this topic, patients learn which findings can be expected and which changes are linked to reassessment. Rising uncertainty can bring the this term appointment forward.
A the finding file is clearer when warning signs, mild but persistent symptoms and treatment expectations are separated; the personal conclusion still depends on examination.
During clinical discussion daily-life impact supports follow-up timing discussion.
For the first assessment daily-life impact supports follow-up timing discussion.
Before the visit prior treatment response supports follow-up timing discussion.
Surveillance Frequency and Criteria
ACR TI-RADS surveillance table: TR5 benign FNA → US at 1 and 2 years; TR4 benign → US at 1 and 2 years; TR3 benign → US at 2 and 4 years; TR1–2 → no surveillance needed. ATA 2015 high-suspicion (white) benign → US at 6–12 months; low-intermediate suspicion (grey) → US at 12–24 months. After two consecutive stable US studies, a final check at 3–5 years may be performed. TI-RADS features and new suspicious characteristics must be reassessed at every surveillance US.
Criteria for Biopsy or Surgery
Indications for biopsy during surveillance: size increase (≥20% or ≥2 mm), new microcalcification, new extrathyroidal growth, or new suspicious lymph node. Repeatedly non-diagnostic (Bethesda I) biopsy: a third biopsy or diagnostic lobectomy is recommended. Multiple benign results: US surveillance frequency may be reduced.
When to Seek Care
During surveillance, rapid nodule growth, new hoarseness, or dysphagia should prompt early evaluation at an endocrinology or ENT clinic without waiting for the scheduled US.
Frequently asked questions
What is Thyroid Nodule Surveillance Protocol?
When is Thyroid Nodule Surveillance Protocol clinically important?
When is ENT assessment relevant for Thyroid Nodule Surveillance Protocol?
What information helps assessment of Thyroid Nodule Surveillance Protocol?
Learn more about this procedure
Detailed guide from Prof. Dr. Özdoğan's clinic
Related terms
References
This glossary entry is for informational purposes only and does not constitute medical advice. Consult a qualified specialist for diagnosis and treatment.